Dr. Thomas T. Amatruda III, MD

Dr. Amatruda practices at Baptist Health Hardin in Elizabethtown, Kentucky, part of Baptist Health.

Dr. Amatruda's NPI, 1427068618, was assigned on August 9, 2006. Dr. Amatruda graduated from Yale School of Medicine in 1978. Dr. Amatruda holds Minnesota license 35894.

Dr. Amatruda's primary practice is Baptist Health Hardin, at 913 North Dixie Avenue, Elizabethtown, KY 42701 in Hardin County. The practice phone is (270) 737-1212.

Dr. Amatruda's primary practice is Baptist Health Hardin in Elizabethtown, Kentucky, part of Baptist Health. Dr. Amatruda is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is Baptist Health Medical Group. Dmand AI also links Dr. Amatruda to 2 more hospitals, 2 medical groups, 1 group practice or clinic and 1 skilled nursing facility, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Amatruda practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Amatruda's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Amatruda is board certified in internal medicine by the American Board of Internal Medicine. Dr. Amatruda is licensed in Minnesota.

Dmand AI lists breast cancer, chronic anemia, colorectal cancer, lung cancer, lymphoma and multiple myeloma among the conditions Dr. Amatruda treats.

CMS data shows 16,107 Medicare services from Dr. Amatruda across 24 procedure codes in 2024, for 251 Medicare patients. Medicare paid $318,955 for them.

CMS counts 251 Medicare patients who saw Dr. Amatruda in 2024. The largest group is 65 to 74, with 94 patients. 66% of them have high blood pressure, and 61% have high cholesterol. 11% are also on Medicaid. Their average risk score is 2.67, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Amatruda's median patient age at 70, with 52% women.

In 2024, Dr. Amatruda wrote 627 Medicare Part D claims for 99 patients. 77% of them were for generic drugs. CMS names the drug for 382 of them, across 19 drugs with 11 or more claims each, at $1,034,088 in total drug cost. In 2023, CMS named 354 claims across 19 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Amatruda for performance year 2024, reported through an alternative payment model (APM).

Dmand AI links 31 papers to Dr. Amatruda, published from 2009 to 2022. 2019 was the busiest year, with 2. The most frequent topics are Melanoma, Skin Neoplasms and Antineoplastic Combined Chemotherapy Protocols. Dr. Amatruda has published most often in J Clin Oncol. Dr. Amatruda's most frequent co-authors are Jose Lutzky, MD, Michael B. Atkins, MD and Robert O. Dillman, MD, FACP.

Dmand AI links Dr. Amatruda to 2 clinical trials. Conditions studied include Melanoma, Neoplasm Metastasis and Nevi and Melanomas.

CMS Open Payments shows 7 general payments to Dr. Amatruda from 4 drug and device companies from 2020 to 2023. Consulting fees make up the largest share, 98% of the total. Novartis Pharmaceuticals Corporation paid the most, $2,025. It also lists 2 research payments totaling $14,000 from 2019 to 2022.

Dmand AI lists 2 awards for Dr. Amatruda, most recently Regional Top Doctor in 2014.

Dr. Amatruda graduated from Yale School of Medicine in 1978.

Dr. Amatruda is in network with 16 carriers, including Aetna, Elevance and Medica. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.